New study tracks joint health in hemophilia a patients on prophylaxis
NCT ID NCT06684314
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study in Taiwan will follow about 100 people with moderate to severe hemophilia A who are already taking efanesoctocog alfa (a clotting factor) as part of their routine care. Researchers will track joint health, bleeding rates, and safety over up to 5 years using medical records and imaging. The goal is to see how well the medicine works in everyday life to protect joints and reduce bleeds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- efanesoctocog alfa (a clotting factor medicine)
- What this could lead to
- If successful, this study could show that efanesoctocog alfa helps protect joints and reduce bleeding in people with hemophilia A in real-world use.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also small (100 participants) and limited to Taiwan, so findings may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Investigational Site Number : 1580001
RECRUITINGTaipei, 100, Taiwan
-
Investigational Site Number : 1580002
RECRUITINGTaipei, 114, Taiwan
-
Investigational Site Number : 1580003
RECRUITINGTaipei, 110, Taiwan
-
Investigational Site Number : 1580004
RECRUITINGTaoyuan City, 33305, Taiwan
-
Investigational Site Number : 1580005
RECRUITINGTaichung, 40201, Taiwan
-
Investigational Site Number : 1580006
RECRUITINGTaichung, 40447, Taiwan
-
Investigational Site Number : 1580007
RECRUITINGTaichung, 40705, Taiwan
-
Investigational Site Number : 1580008
RECRUITINGChanghua, 500, Taiwan
-
Investigational Site Number : 1580009
RECRUITINGKaohsiung City, 807, Taiwan
-
Investigational Site Number : 1580010
RECRUITINGKaohsiung City, 83301, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Can a new clotting factor offer better bleed protection for severe hemophilia?
- Do newer hemophilia drugs protect joints better? study aims to find out
- Newborn screening study aims to catch rare diseases at birth
- Could home blood tests transform hemophilia care? study seeks patient views
- New clotting factor shows promise for hemophilia a bleeds